ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för ixabepilone. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

15 träffar

Bibliografisk träff 2011-11-22

RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer.

Vishnu P, Colon-Otero G, Kennedy GT, Marlow LA, Kennedy WP, Wu KJ, Santoso JT, Copland JA.

Gynecol Oncol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.ygyno.2011.11.019

Bibliografisk träff 2011-11-20

The paradox of triple negative breast cancer: novel approaches to treatment.

Fornier M, Fumoleau P.

Breast J · research support, non-u.s. gov't; review; journal article · DOI 10.1111/j.1524-4741.2011.01175.x

Bibliografisk träff 2011-09-21

Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.

Jassem J, Fein L, Karwal M, Campone M, Peck R, Poulart V, Vahdat L.

Breast · clinical trial, phase iii; research support, non-u.s. gov't; journal article · DOI 10.1016/j.breast.2011.09.003

Bibliografisk träff 2011-05-19

Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.

Corey-Lisle PK, Peck R, Mukhopadhyay P, Orsini L, Safikhani S, Bell JA, Hortobagyi G, Roche H, Conte P, Revicki DA.

Cancer · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/cncr.26213

Bibliografisk träff 2011-05-19

Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance.

Edelman MJ, Shvartsbeyn M.

Clin Lung Cancer · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.cllc.2011.02.005

Bibliografisk träff 2011-05-17

Ixabepilone for the treatment of breast cancer.

Alvarez RH, Valero V, Hortobagyi GN.

Ann Med · research support, non-u.s. gov't; review; journal article · DOI 10.3109/07853890.2011.579151

Bibliografisk träff 2011-05-01

Global experience with ixabepilone in breast cancer.

Kaklamani VG, Xu BH, Gomez HL.

Expert Rev Anticancer Ther · review; journal article · DOI 10.1586/era.11.41

Bibliografisk träff 2011-04-20

Ixabepilone: clinical role in metastatic breast cancer.

Denduluri N, Swain S.

Clin Breast Cancer · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.clbc.2011.03.009

Bibliografisk träff 2011-04-01

Epothilones in the treatment of ovarian cancer.

Diaz-Padilla I, Oza AM.

Future Oncol · research support, non-u.s. gov't; review; journal article · DOI 10.2217/fon.11.26

Bibliografisk träff 2011-01-24

Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).

Shen H, Lee FY, Gan J.

J Pharmacol Exp Ther · research support, non-u.s. gov't; journal article · DOI 10.1124/jpet.110.175604

Bibliografisk träff 2011-01-13

Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.

Rak Tkaczuk KH.

Breast Cancer (Auckl) · review-article; journal article · DOI 10.4137/bcbcr.s5331

Bibliografisk träff 2011-01-01

Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence.

Lee F, Jure-Kunkel MN, Salvati ME.

Ther Adv Med Oncol · review-article; journal article · DOI 10.1177/1758834010386402

Bibliografisk träff 2010-12-03

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies.

Roché H, Conte P, Perez EA, Sparano JA, Xu B, Jassem J, Peck R, Kelleher T, Hortobagyi GN.

Breast Cancer Res Treat · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1007/s10549-010-1251-y

Bibliografisk träff 2010-10-27

Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients.

Kossoff EB, Ngamphaiboon N, Laudico TJ, O'Connor TL.

Med Oncol · journal article · DOI 10.1007/s12032-010-9726-6

Bibliografisk träff 2010-03-09

Alternative dosing schedules and administration updates for ixabepilone.

Kossoff E.

J Oncol Pharm Pract · review; journal article · DOI 10.1177/1078155210364273